ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1046

Differences in Disease Activity by Sex and Pubertal/Menopausal Status in Primary Glomerulonephropathies

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Oliverio, Andrea L., University of Michigan, Ann Arbor, Michigan, United States
  • Mansfield, Sarah, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Almaani, Salem, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Ayoub, Isabelle, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Clark, Kira, Oregon Health and Science University, Portland, Oregon, United States
  • Fernandez, Hilda E., NYP-CUMC, New York, New York, United States
  • Khairallah, Pascale, Columbia University Medical Center, New York, New York, United States
  • O'Shaughnessy, Michelle M., Stanford University, Palo Alto, California, United States
  • Reynolds, Monica Lona, University of North Carolina at Chapel Hill, Cary, North Carolina, United States
  • Twombley, Katherine, Medical University of South Carolina, Charleston, South Carolina, United States
  • Wadhwani, Shikha, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Vasylyeva, Tetyana L., Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Hladunewich, Michelle A., University of Toronto, Toronto, Ontario, Canada
  • Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States

CKD has been observed to progress more slowly in women than men. However, large studies examining associations between sex, reproductive stage, and disease activity and progression in primary glomerulonephropathies are lacking.


CureGN is a 70-site prospective cohort study of patients with MCD, FSGS, IgAN/IgAV, or MN. Patients with available eGFR, UPCR, and reproductive stage at enrollment were studied. Reproductive stage was categorized as pre-pubertal (Tanner stage I-III), post-pubertal (Tanner stage IV-V, or menarche for females), or post-menopausal (females only). Multivariable mixed linear models adjusted for baseline data at time of enrollment (Table) were fit to examine change in eGFR and UPCR over time.


Median follow-up from enrollment was 2.1 (IQR 1.0-3.1) yrs. Among 1202 patients with available enrollment eGFR, adjusted (Model 3) eGFR slopes amongst females were +0.71, -0.84, and -1.43 ml/min/1.73m2 per year for pre-pubertal, post-pubertal, and post-menopausal women, respectively (Table). For pre-pubertal and post-pubertal males, eGFR slopes were -1.14 and -1.19 ml/min/1.73m2 per year, respectively. Adjusted UPCR slopes by sex and reproductive stage are also shown in the Table.


The protective effect of female sex on eGFR decline was most notable prior to puberty. Of all groups, post-menopausal women had the fastest eGFR decline. Unlike post-pubertal males and females, pre-pubertal participants experienced no significant decrease in UPCR over time, and menopausal status did not seem to impact the rate of UPCR decline seen in post-pubertal females.


  • NIDDK Support